Furthermore, systemic deletion of Deptor in a Pten+/− transgenic mouse was shown to promote prostate tumorigenesis accompanied with increased mTORC1/2 signaling, suggesting that the restoration of DEPTOR could be a beneficial therapeutic approach for PTEN-deficient prostate cancer [220]. Here, PTEN is linked to prostate carcinoma.